Reynders Mc Veigh Capital Management, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Reynders Mc Veigh Capital Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$692.45 - $844.37 $3,462 - $4,221	5 Added 1.78%	286 $235,000
Q2 2023 Aug 09, 2023	SELL	$700.03 - $830.35 $700 - $830	-1 Reduced 0.35%	281 $202,000
Q4 2022 Feb 10, 2023	SELL	$705.89 - $766.39 $273,179 - $296,592	-387 Reduced 57.85%	282 $203,000
Q2 2022 Aug 05, 2022	SELL	$548.35 - $738.84 $3,838 - $5,171	-7 Reduced 1.04%	669 $395,000
Q1 2022 May 11, 2022	SELL	$595.12 - $698.43 $14,878 - $17,460	-25 Reduced 3.57%	676 $472,000
Q4 2021 Feb 11, 2022	SELL	$543.48 - $670.97 $129,348 - $159,690	-238 Reduced 25.35%	701 $443,000
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $185,411 - $219,950	-323 Reduced 25.59%	939 $568,000
Q2 2021 Aug 12, 2021	SELL	$472.8 - $558.54 $60,045 - $70,934	-127 Reduced 9.14%	1,262 $705,000
Q1 2021 May 07, 2021	SELL	$446.73 - $548.2 $77,731 - $95,386	-174 Reduced 11.13%	1,389 $657,000
Q4 2020 Feb 10, 2021	SELL	$478.3 - $607.98 $73,658 - $93,628	-154 Reduced 8.97%	1,563 $755,000
Q3 2020 Oct 28, 2020	SELL	$544.75 - $658.21 $43,580 - $52,656	-80 Reduced 4.45%	1,717 $961,000
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $22,199 - $28,976	-45 Reduced 2.44%	1,797 $1.12 Million
Q1 2020 May 13, 2020	BUY	$336.18 - $494.43 $2,353 - $3,461	7 Added 0.38%	1,842 $899,000
Q1 2019 May 10, 2019	BUY	$372.08 - $439.57 $186,040 - $219,785	500 Added 37.45%	1,835 $753,000
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $448,319 - $538,058	1,335 New	1,335 $499,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.